Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK140944)
Abstract Background With increasing concerns about the impact of frequent antibiotic usage on the human microbiome, it is important to characterize the potential for such effects in early antibiotic drug development clinical trials. In a randomised Phase 2a clinical trial study that evaluated the ph...
Main Authors: | Andrea Nuzzo, Stephanie Van Horn, Christopher Traini, Caroline R. Perry, Etienne F. Dumont, Nicole E. Scangarella-Oman, David F. Gardiner, James R. Brown |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-06-01
|
Series: | BMC Microbiology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12866-021-02245-8 |
Similar Items
-
Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female Participants
by: Caroline Perry, et al.
Published: (2022-10-01) -
Efficacy and Safety of Gepotidacin as Treatment of Uncomplicated Urogenital Gonorrhea (EAGLE-1): Design of a Randomized, Comparator-Controlled, Phase 3 Study
by: Caroline R. Perry, et al.
Published: (2023-09-01) -
Correction to: Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK2140944)
by: Andrea Nuzzo, et al.
Published: (2021-10-01) -
In vitro activity of the first-in-class triazaacenaphthylene gepotidacin alone and in combination with doxycycline against drug-resistant and -susceptible Mycoplasma genitalium
by: Jørgen Skov Jensen, et al.
Published: (2020-01-01) -
Antibacterial Activity of the Novel Drug Gepotidacin against <i>Stenotrophomonas maltophilia</i>—An In Vitro and In Vivo Study
by: Maike Isabell Sanders, et al.
Published: (2022-02-01)